Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative diagnostic and treatment modalities for patients suffering from mild to moderate obstructive sleep apnea (“OSA”) and snoring, is reporting significant increases across several key metrics for its SleepImage Home Sleep Apnea Tests (“HST”) during the three-month period that ended Dec. 31, 2021. Specifically, the company noted an 18 times increase in the total number of HSTs given by its network of trained dentists, called Vivos Integrated Practices or VIPs as well as a 5.7 times increase in the number of VIPs administering HSTs and a 3 times increase in the average number of HSTs being administered per VIP. Vivos also announced an improved pricing agreement with SleepImage that includes dramatically lower costs. “We have always believed that the pathway to getting more patients into treatment for OSA begins with an easy, inexpensive and highly accurate diagnostic process, which is precisely what the proprietary SleepImage test delivers,” said Vivos chair and CEO Kirk Huntsman in the press release. “When coupled with the telemedicine model we have through our collaboration with Empower Sleep, which allows for the required medical diagnosis of OSA remotely, we believe that an historical barrier to patients obtaining a clear and medically valid sleep test report has now been eliminated. The number of positive OSA tests we are seeing is staggering, demonstrating the potential that is available for our Vivos System treatment for OSA. Having now familiarized our VIPs with the prevalence of OSA and giving them a way to test for OSA, our goal will be to use this data to continue to encourage VIPs to get their patients who test positive for OSA into treatment with the Vivos System. Converting positive OSA tests using our HSTs into Vivos System case starts is a major focus of our Practice Advisors and support personnel at Vivos as we roll into 2022. We also expect that our new pricing arrangement with SleepImage will yield positive financial results for Vivos.”
To view the full press release, visit https://ibn.fm/uOX62
About Vivos Therapeutics Inc.
Vivos Therapeutics is a medical technology company focused on developing and commercializing innovative diagnostic and treatment modalities for adult patients suffering from mild-to-moderate obstructive sleep apnea (“OSA”). The Vivos treatment involves customized oral appliances and treatment protocols called the Vivos System. Vivos believes that its Vivos System oral appliance technology represents the first clinically effective, nonsurgical, noninvasive, nonpharmaceutical and cost-effective solution for adults with mild-to-moderate OSA. Vivos also sells orthodontic appliances for adults and children. Vivos’ oral appliances have proven effective in the treatment of more than 24,000 patients worldwide by more than 1,350 trained dentists. Combining technologies and protocols that alter the size, shape and position of the tissues of a patient’s upper airway, the Vivos System opens airway space and may significantly reduce symptoms and conditions associated with mild-to-moderate OSA, such as lowering Apnea Hypopnea Index scores. Vivos also markets and distributes SleepImage diagnostic technology, powered by VivosScore for home sleep testing in adults and children. The Vivos Integrated Practice (“VIP”) program offers dentist training and other value-added services in connection with using the Vivos System. For more information about this company, visit www.VivosLife.com.
NOTE TO INVESTORS: The latest news and updates relating to VVOS are available in the company’s newsroom at http://ibn.fm/VVOS
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@InvestorWire.com
InvestorWire is part of the InvestorBrandNetwork.